Address
Pfizer Inc
235 East 42nd Street
150/39/18
New York, NY 10017
United States
Phone
Website
Sector
Recent investment activity
KANDO id: 4229
Funding rounds
Actual initial investment stage
Acquisition (3)
Fund Closing (1)
Investment activity status
Active investor
Selected investments
Displaying 1 - 25 of 25| Company | Profile | Country | Date Sort descending | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Five Prime Therapeutics Inc | N/A | ||||
|
|
Five Prime Therapeutics Inc | N/A | ||||
|
|
Coley Pharmaceutical Group Inc | N/A | ||||
|
|
Ablexis LLC | Biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery. | N/A | |||
|
|
Excaliard Pharmaceuticals Inc | N/A | ||||
|
|
Esperion Therapeutics Inc | N/A | ||||
|
|
NeuroTherapeutics Pharma Inc | N/A | ||||
|
|
Celladon Corp | N/A | ||||
|
|
IDUN Pharmaceuticals Inc | Acquisition | ||||
|
|
Vicuron Pharmaceuticals Inc | Acquisition USD 1,900,000,000 (USD 1,900,000,000) | ||||
|
|
Avid Radiopharmaceuticals Inc | Series A | ||||
|
|
BioRexis Pharmaceutical Corp | Acquisition | ||||
|
|
Avid Radiopharmaceuticals Inc | Series C | ||||
|
|
Serenex Inc | Oncology-focused drug development company | Acquisition | |||
|
Wyeth Pharmaceuticals | Acquisition Initial investment USD 68,000,000,000 (USD 68,000,000,000) | ||||
|
|
Avid Radiopharmaceuticals Inc | Series D | ||||
|
|
TetraLogic Pharmaceuticals | A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. | Series C (USD 5,000,000) | |||
|
|
FoldRx Pharmaceuticals Inc | Acquisition | ||||
|
|
King Pharmaceuticals | Acquisition Initial investment led the round USD 3,600,000,000 (USD 3,600,000,000) | ||||
|
|
Neuronetics Inc | Series E | ||||
|
|
DVS Sciences Inc | An analytical instrument and reagents company founded in Toronto | Series A | |||
|
|
Icagen Inc | Biopharmaceutical company developing small molecule therapeutics that target ion channels for treatment of a variety of diseases. | Acquisition USD 56,000,000 (USD 56,000,000) | |||
|
Anacor Pharmaceuticals Inc | Acquisition Initial investment led the round USD 5,200,000,000 (USD 5,200,000,000) | ||||
|
Medivation Inc | Acquisition USD 14,000,000,000 (USD 14,000,000,000) | ||||
|
Phoenix Venture Partners II LP | Venture capital fund focused on advanced materials startups. | Fund Closing Initial investment |
Team
| Employee | Position | |||
|---|---|---|---|---|
| Barbara J Dalton | Vice President
Venture Capital |
[email protected] |
